HIT Consultant February 14, 2022
What You Should Know:
– Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in C-2 funding led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech.
– Founded in 2014, the Variantyx proprietary whole genome sequencing and analysis platforms allow healthcare providers and their patients to better understand a...
Today's Sponsors
Today's Sponsor